Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129887 | 0.85 | CYP2D6 (1.00) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL12129582 | 0.84 | CYP19A1 (0.69) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL5751218 | 0.83 | CYP19A1 (0.73) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL13527207 | 0.83 | CYP2D6 (0.94) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL14080906 | 0.82 | CYP19A1 (0.71) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL4861343 | 0.82 | CYP19A1 (0.71) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL10338918 | 0.81 | CYP19A1 (0.76) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL9435138 | 0.81 | CYP2D6 (0.91) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL9650521 | 0.81 | CYP2D6 (0.91) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL15740967 | 0.81 | CYP2D6 (0.91) | CYP3A4CYP19A1CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION | 2023-11-23 | — | — | US | disclosed |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| CN-108864076-A | glucosylceramide synthase inhibitors | 建新公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-102958918-B | Novel tobacco amide derivatives or its salt | FUJIFILM CORP. (JP) | 2015-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | CYP3A4 4189/4885CYP19A1 3771/4885CYP2D6 2850/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | CYP3A4 4870/4885CYP19A1 4793/4885CYP2D6 4777/4885 |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GBA1, GBA2, GALC | CYP3A4 2006/4885CYP19A1 1180/4885CYP2D6 1316/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | CYP3A4 2522/4885CYP19A1 1773/4885CYP2D6 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.